NormOxys has discovered and is currently developing a proprietary technology platform that generates a novel class of small molecule drugs, oxyrens, which enhance the body’s ability to deliver oxygen more efficiently to diseased tissues with oxygen deficiency. This new class of drugs can be potentially developed in a broad range of clinical indications where therapeutic benefit can be obtained through an increased, regulated delivery of oxygen to hypoxic tissue. Potential clinical indications include cancer, cardiovascular diseases, anemia, stroke and diabetic retinopathy. NormOxys’ lead compound, OXY111A, is currently in Phase I clinical trials.